Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review

Immune checkpoint inhibitors (ICIs) are drugs growingly employed in the treatment of cancers, but there are still uncertainties about their possible role in the risk of developing nontuberculous mycobacteria (NTM) infections. To understand this, we performed a systematic review of the literature inc...

Full description

Saved in:
Bibliographic Details
Published in:ERJ open research 2022-10, Vol.8 (4), p.364
Main Authors: Lombardi, Andrea, Gramegna, Andrea, Ori, Margherita, Azzarà, Cecilia, Blasi, Francesco, Gori, Andrea
Format: Article
Language:English
Subjects:
Original s
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICIs) are drugs growingly employed in the treatment of cancers, but there are still uncertainties about their possible role in the risk of developing nontuberculous mycobacteria (NTM) infections. To understand this, we performed a systematic review of the literature including studies published between 20 June 2012 and 20 June 2022 which described the occurrence of NTM infections among patients treated with ICIs. Overall, we included seven studies describing nine patients with NTM infection occurring during ICIs therapy. NTM infections occurring during ICIs therapy are mainly caused by germs belonging to the Mycobacterium avium complex , involve primarily the lungs, on average 1 year after the start of treatment, and are not associated with immunosuppressive treatments.
ISSN:2312-0541
2312-0541
DOI:10.1183/23120541.00364-2022